雷美替胺诱发的噩梦：一例报告。

Ramelteon-induced nightmares: A case report.

作者信息

Shah Chintan, Kablinger Anita

机构信息

Department of Psychiatry & Behavioral Medicine, Carilion Clinic-Virginia Tech Carilion, First Floor Administrative Suites, 2017 South Jefferson Street, Roanoke 24014, VA, United States.

出版信息

Asian J Psychiatr. 2015 Dec;18:111-2. doi: 10.1016/j.ajp.2015.09.004. Epub 2015 Sep 21.

DOI:10.1016/j.ajp.2015.09.004

PMID:26427581

Abstract

Ramelteon is the only FDA-approved melatonin agonist for treatment of insomnia. It acts on melatonin MT1 and MT2 receptors. We describe a case of a patient who was prescribed ramelteon for insomnia disorder. Shortly after initiation of ramelteon, he described vivid nightmares leading to discontinuation of ramelteon. The nightmares ameliorated with ramelteon discontinuation. Ramelteon is well tolerated with a favorable side-effect profile. No documented cases of nightmares secondary to ramelteon use were found in the literature. The effects of ramelteon on rapid eye movement sleep, the stage of sleep where dreams occur, need to be further explored.

摘要

雷美替胺是唯一经美国食品药品监督管理局（FDA）批准用于治疗失眠的褪黑素激动剂。它作用于褪黑素MT1和MT2受体。我们描述了一例被处方使用雷美替胺治疗失眠症的患者。在开始使用雷美替胺后不久，他称出现了生动的噩梦，导致雷美替胺停药。停用雷美替胺后噩梦有所改善。雷美替胺耐受性良好，副作用较小。文献中未发现有记录的因使用雷美替胺而导致噩梦的病例。雷美替胺对快速眼动睡眠（即做梦发生的睡眠阶段）的影响有待进一步研究。